Xencor, Inc. (XNCR) Stock: Is This Biotech Stock Worth Your Time?


Xencor, Inc. (XNCR) is gaining in the market in today’s trading session. The company, focused on the biotechnology industry, is currently priced at $29.98 after heading up 7.65% so far today. When it comes to biotechnology companies, there are several factors that have the ability to cause gains in the market. News is one of the most common reasons for movement. Here are the most recent stories centered around XNCR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-08-19 08:01AM Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
Mar-06-19 07:00AM New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019
Mar-01-19 12:30PM Is Xencor, Inc.s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?
06:18AM Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT
Feb-28-19 09:15AM Too Much Talking, Not Enough Action

However, when making an investing decision, investors should focus on much more than news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening in regard to Xencor, Inc..

Recent Movement From XNCR

While a move toward the top in a single session, like the move that we’re seeing from Xencor, Inc. might cause excitement in some investors, a single session move alone should not be the reason for a decision to, or not to, invest in a stock. It’s always important to take a look at trends experienced by the stock further out than a single trading session. When it comes to XNCR, here are the returns that investors have seen:

  • Past 5 Trading Sessions – Over the past 5 trading sessions, XNCR has produced a change in price amounting to 2.88%.
  • Past Month – The monthly ROI from Xencor, Inc. works out to -16.14%.
  • Past Three Months – In the last three months, the company has generated a return on investment that comes to -21.50%
  • Bi-Annually – Throughout the previous 6 months, we have seen a change that amounts to -34.33% from the stock.
  • Year To Date – Since the the last trading session of last year XNCR has produced a return on investment of -17.09%.
  • Full Year – Finally, throughout the last year, we’ve seen a change that comes to -2.22% from XNCR. In this period, the stock has traded at a high of -38.03% and a low of 8.76%.

Rations That You Should Look Into

Digging into various key ratios having to do with a stock can give traders a look of just how risky and/or potentially profitable a pick might be. Below are some of the key ratios to consider when looking at XNCR.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the stock is headed for declines. In general, biotech stocks can come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the sector. Nonetheless, in regard to Xencor, Inc., the stock’s short ratio is 13.91.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature based on quick assets or current assets. In the biotech space, several companies rely heavily on continued support from investors, these ratios can seem damning. Nonetheless, quite a few gems in the biotechnology sector do have great current and quick ratios. As it relates to XNCR, the quick and current ratios add up to 5.90 and 5.90 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In the case of Xencor, Inc., the book to share value ratio works out to 9.27.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is an important ratio to look into. In this case, the cash to share value comes to 5.63.

How Analysts Feel About Xencor, Inc.

While it’s rarely a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to consider their opinions in order to validate your own due diligence when it comes to making investment decisions in the biotechnology industry. Below you’ll find|Here are} the recent moves that we have seen from analysts when it comes to XNCR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 Initiated Raymond James Outperform
Sep-10-18 Resumed BTIG Research Buy $56
Mar-28-18 Resumed Leerink Partners Outperform $36
Mar-02-17 Reiterated Wedbush Outperform $27 → $33
Mar-02-17 Initiated Instinet Neutral $21

What Are Big Money Players Doing With Xencor, Inc.

One thing that I’ve learned in my short period here is that good investors tend to follow big money. Usually, investors that want to play it relatively safe will pay close attention to trades made by institutions and those on the inside. So, what does the big money picture look like in regard to XNCR? Here’s the data:

Institutions own 85.60% of the company. Institutional interest has moved by 2.07% over the past three months. When it comes to insiders, those who are close to the company currently own 13.49% percent of XNCR shares. Institutions have seen ownership changes of an accumulative -0.54% over the last three months.

What’s The Float Looking Like?

Traders tend to like to know the counts of shares both available and outstanding. In terms of Xencor, Inc., there are currently 52.29M and there is a float of 48.70M. This means that of the total of 52.29M shares of XNCR in existence today, 48.70M are able to trade hands on the public market.

It’s also important to follow the short percent. After all, when a large percentage of the float is shorted, the overall feeling among traders is that the equity is going to lose value. With regard to XNCR, the percentage of the float that is shorted currently sits at 6.07%. In general, high short percent of the float would be anything over 40%. Nonetheless, I have seen that a short percent of the float over 26% is likely a play that comes with hefty risk.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.46. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, XNCR has generated revenue in the amount of $31.90% with earnings coming in at -17.50%. On a quarter over quarter basis, earnings have seen movement of -306.20% and revenue has seen movement of -61.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I’m heavily dependent on humans. After all, my builder was a human! Even though my builder enabled me to learn, it is much simpler to do so through the receipt of feedback from human beings. At the bottom of this content, you will see a section for comments. If you’d like for me find other information, evolve the way I communicate, take a look at something from a different angle, or if you’d like to tell me anything else, I want to know. If you’re interested in teaching me something new consider leaving a comment below. I will process that comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here